Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Public ClinicalTrials.gov record NCT07028749. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)
Study identification
- NCT ID
- NCT07028749
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Marea Therapeutics
- Industry
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Interventions
- MAR001 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2025
- Primary completion
- Jun 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Jan 25, 2026
2025 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Marea Site 328 | Anniston | Alabama | 36207 | — |
| Marea Site 329 | Mobile | Alabama | 36608 | — |
| Marea Site 313 | Little Rock | Arkansas | 72204 | — |
| Marea Site 306 | Hamden | Connecticut | 06517 | — |
| Marea Site 302 | Boca Raton | Florida | 33434 | — |
| Marea Site 307 | Port Saint Lucie | Florida | 34952 | — |
| Marea Site 310 | Columbus | Georgia | 31904 | — |
| Marea Site 319 | Peachtree Corners | Georgia | 30092 | — |
| Marea Site 317 | Park Ridge | Illinois | 60068 | — |
| Marea Site 325 | Springfield | Illinois | 62702 | — |
| Marea Site 301 | Louisville | Kentucky | 40213 | — |
| Marea Site 316 | Baltimore | Maryland | 21229 | — |
| Marea Site 330 | Kansas City | Missouri | 64151 | — |
| Marea Site 305 | St Louis | Missouri | 63110 | — |
| Marea Site 304 | Great Neck | New York | 11021 | — |
| Marea Site 318 | New Windsor | New York | 12553 | — |
| Marea Site 303 | Greensboro | North Carolina | 27405 | — |
| Marea Site 315 | Winston-Salem | North Carolina | 27104 | — |
| Marea Site 314 | Greenville | South Carolina | 29607 | — |
| Marea Site 320 | Little River | South Carolina | 29566 | — |
| Marea Site 326 | Memphis | Tennessee | 38119 | — |
| Marea Site 322 | Amarillo | Texas | 79124 | — |
| Marea Site 308 | McKinney | Texas | 75071 | — |
| Marea Site 312 | San Antonio | Texas | 78229 | — |
| Marea Site 321 | Manassas | Virginia | 20109 | — |
| Marea Site 309 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07028749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07028749 live on ClinicalTrials.gov.